Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Organisation › Details

Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). *


Period Start 2002-01-01 splitoff
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 Intuvax®
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Zeilemaker, Sijme (Immunicum 201703– Director Business Development before InteRNA Technologies + to-BBB Technologies)
Region Region Göteborg (Gothenburg)
  Country Sweden
  Street 2 Grafiska Vägen
  City 412 63 Göteborg
  Tel +46-31-415052
    Address record changed: 2016-05-07
Basic data Employees B: 11 to 50 (2017-12-31)
  Currency SEK
  Annual sales 217,903 (income, operating (2017) 2017-12-31)
  Profit -80,337,643 (2017-12-31)
  Cash 128,882,939 (2017-12-31)
    * Document for �About Section�: Immunicum AB. (4/25/16). "Press Release: Immunicum Announces Fully Underwritten Rights Issue of about SEK 111 Million to Extend Phase II-Trial with New clinics in the US and to Initiate Clinical Trials in Melanoma in the US and in Sweden".
Record changed: 2018-10-20


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top